Results 1 to 10 of about 21,933 (136)

Periorbital edema secondary to imatinib mesylate [PDF]

Clinical Ophthalmology, 2010
Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Collin M McClelland, George J Harocopos, Philip L Custer   +2 more
doaj   +2 more sources

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity [PDF]

International Journal of Nanomedicine, 2015
Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological ...
Marslin G, Revina AM, Khandelwal VKM, Balakumar K, Prakash J, Franklin G, Sheeba CJ   +6 more
doaj   +3 more sources

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes

Drug Design, Development and Therapy, 2017
Ali Kadivar,1 Behnam Kamalidehghan,1 Hamid Akbari Javar,2 Benyamin Karimi,3 Reihaneh Sedghi,4 Mohamed Ibrahim Noordin1 1Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2Department of Pharmaceutics, Faculty of ...
Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R, MI Noordin   +5 more
doaj   +1 more source

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report

Revista Colombiana de Cardiología, 2008
La cardiotoxicidad por medicamentos es un evento cada vez más frecuente en la práctica clínica diaria. Inhibidores de la proteína de fusión Brc/Abl como el imatinib mesilato, son una nueva herramienta para el tratamiento de algunas neoplasias ...
Clara Saldarriaga, Jairo A Rendón, Juan M Senior   +2 more
doaj  

Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia

Haematologica, 2003
BACKGROUND AND OBJECTIVES: We compared the early cytogenetic response (CgR) to a combination of imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) and a pegylated form of human recombinant interferon-alpha2b (pegIFN-alpha2b, PegIntron ...
G Rosti, E Trabacchi, S Bassi, F Bonifazi, A de Vivo, G Martinelli, D Alberti, G Fincato, G Saglio, M Baccarani, Italian Cooperative Study Group on Chronic Myeloid Leukemia   +10 more
doaj  

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Brazilian Journal of Pharmaceutical Sciences
Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic ...
Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres   +4 more
doaj   +1 more source

Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia

Haematologica, 2003
We report a chronic myeloid leukemia (CML) patient in chronic phase (CP) who developed blast crisis (BC) under imatinib mesylate administered in a dose reduced and non-continuous fashion because of hematologic intolerance.
PB Staber, R Brezinschek, W Linkesch, H Sill, P Neumeister   +4 more
doaj  

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation

Haematologica, 2006
Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions.
M Weisser, J Tischer, S Schnittger, C Schoch, G Ledderose, HJ Kolb   +5 more
doaj  

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression

Haematologica, 2003
BACKGROUND AND OBJECTIVES: The acquisition of additional cytogenetic changes (clonal evolution, CE) during treatment of chronic myeloid leukemia (CML) with imatinib mesylate is currently regarded as an index of increasing resistance to imatinib ...
S Marktel, D Marin, N Foot, R Szydlo, M Bua, A Karadimitris, VA De Melo, P Kotzampaltiris, F Dazzi, A Rahemtulla, E Olavarria, JF Apperley, JM Goldman   +12 more
doaj  

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis

Терапевтический архив, 2010
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease.
Ol'ga Veniaminovna Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva, O V Stakhina, A G Turkina, I E Kostina, Yu B Kochkareva   +7 more
doaj